Navigation Links
Elcelyx Therapeutics' NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
Date:9/4/2013

SAN DIEGO, Sept. 4, 2013 /PRNewswire/ -- Elcelyx Therapeutics announced today that NewMet™, the delayed-release formulation of generic metformin for the treatment of patients with Type 2 diabetes, met its primary study endpoint with statistically significant reductions in fasting plasma glucose at four weeks of treatment compared to placebo. 

The results from the randomized, 240-patient, multicenter U.S. Phase 2b trial confirm previous studies that showed NewMet reduced fasting plasma glucose to a similar extent as generic metformin but at plasma exposure levels previously shown to be as much as 65% lower than comparable doses of generic metformin.

The double-blind, dose-finding trial evaluated NewMet once-daily doses of 1,000, 800 and 600 milligrams compared to placebo. There were also two comparator arms with Glucophage XR dosed once-daily at 1,000 and 2,000 milligrams. Secondary endpoints through 12 weeks include changes in fasting plasma glucose, hemoglobin A1c, body weight and measures of safety and tolerability. Twelve-week results are expected in late October.

The results at four weeks provide confirmation that the primary site of metformin activity is the lower bowel and not the circulation.  The reduced systemic absorption of NewMet indicates that it may be an appropriate treatment for Type 2 diabetes patients who have renal impairment and are contraindicated for metformin use due to the risk of lactic acidosis, a life-threatening condition that can result from metformin build-up in the blood.

About Elcelyx Therapeutics, Inc.

Elcelyx Therapeutics is developing pharmaceutical product candidate NewMet™ for use by Type 2 diabetes patients who have difficulty tolerating generic metformin or are contraindicated for its use. NewMet presents a near-term, blockbuster commercial opportunity. Elcelyx is based in San Diego, CA. For more information, visit www.Elcelyx.com.

 

 


'/>"/>
SOURCE Elcelyx Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Elcelyx Therapeutics Reports Positive Data for NewMet in Type 2 Diabetes at 2013 American Diabetes Association Scientific Sessions
2. Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes
3. Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
4. Elcelyx Therapeutics Names Mark Wiggins Senior Vice President of Business Development, Ginger Graham to Board of Directors
5. Aratana Therapeutics Drives Awareness of Pet Therapeutic Opportunity During "CVC Week" in Kansas City
6. Mast Therapeutics To Present At The Rodman & Renshaw 15th Annual Healthcare Conference On September 10
7. PTC Therapeutics to Present at Upcoming Investor Conferences
8. Aratana Therapeutics to Host Pet Therapeutics Primer and Product Update Event
9. Carolus Therapeutics and The Alpha-1 Project Collaborate to Validate CT-2009 Target as Important in Human Disease
10. Echo Therapeutics Announces Management Changes
11. aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016 REPORT OBJECTIVES ... provides market intelligence on a market segment, based ... been provided in the report. The primary objectives ... global market intelligence through detailed segmentation, 2) market ... structure and developments, market situation, trends, 3) detailed ...
(Date:12/7/2016)... According to the new ... Market, by Components (Software, Service), Delivery Modes (Web-based, ... Biotechnology Companies, Clinical Research Organization, Medical Device Companies) ... to 2022", published by Scalar Market Research, the ... expected to grow at a healthy CAGR of ...
(Date:12/7/2016)... 7, 2016   Rx Savings Solutions has partnered ... and its Public Employees Insurance Agency (PEIA) to offer more ... innovative healthcare software, ultimately saving money on their prescriptions. ... its members with access to our software that will alert ... affordable therapy can be found," says Michael Rea , ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff Hart Agencies, ... South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is announcing ... a brain tumor. , Jason Bauer and his family are longtime members of ...
(Date:12/7/2016)... ... December 07, 2016 , ... AlignLife clinics nationwide are giving back to their ... enough to receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes ... of the world. , In exchange for generous donations, customers will receive a gift ...
(Date:12/7/2016)... ... 07, 2016 , ... The Honolulu cosmetic and medical dermatology ... launched October 17, 2016, features comprehensive information regarding a wide range of dermatologic ... patients can discover the latest clinical dermatology treatments for medical skin concerns as ...
(Date:12/7/2016)... TX (PRWEB) , ... December 07, 2016 , ... ... 2016 Top 20 Marketing Campaign Winner in the Folio: Marketing Awards competition. Live ... recognize the year’s best in pioneering, inventive, and ultimately successful projects undertaken by ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... its newest portable bioelectronic medicine device WellnessPro Plus for consumers and healthcare ... enhances the WellnessPro platform by expanding the treatment modalities available in a ...
Breaking Medicine News(10 mins):